[
    [
        {
            "time": "",
            "original_text": "药明康德、宁德时代之后，又一巨头迈瑞医疗冲刺A股",
            "features": {
                "keywords": [
                    "药明康德",
                    "宁德时代",
                    "迈瑞医疗",
                    "A股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗设备",
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德、宁德时代之后，又一巨头迈瑞医疗冲刺A股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[看好评级]医药生物行业2018年中报业绩前瞻：医疗需求刚性 重点关注稳健成长和“流量入口”型公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报业绩",
                    "医疗需求",
                    "稳健成长",
                    "流量入口"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[看好评级]医药生物行业2018年中报业绩前瞻：医疗需求刚性 重点关注稳健成长和“流量入口”型公司",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "[买入评级]医药生物行业7月月报：调整中布局下半年行情",
            "features": {
                "keywords": [
                    "医药生物",
                    "买入评级",
                    "调整",
                    "下半年行情"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]医药生物行业7月月报：调整中布局下半年行情",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业周报：市场或迎来中级反弹 防御为先医药为上",
            "features": {
                "keywords": [
                    "医药生物",
                    "增持评级",
                    "中级反弹",
                    "防御"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业周报：市场或迎来中级反弹 防御为先医药为上",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药行业卓越推：华兰生物(002007)、天坛生物(600161)",
            "features": {
                "keywords": [
                    "医药行业",
                    "华兰生物",
                    "天坛生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业卓越推：华兰生物(002007)、天坛生物(600161)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药生物行业2018年中报业绩前瞻：重点覆盖公司中报业绩前瞻：关注2季度增速加快个股",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报业绩",
                    "推荐评级",
                    "2季度增速"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药生物行业2018年中报业绩前瞻：重点覆盖公司中报业绩前瞻：关注2季度增速加快个股",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "上半年业绩暴增股备受资金青睐 三股同比增幅超前",
            "features": {
                "keywords": [
                    "上半年业绩",
                    "暴增股",
                    "资金青睐",
                    "同比增幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上半年业绩暴增股备受资金青睐 三股同比增幅超前",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业周报：布局政策免疫品种 推荐二线细分龙头",
            "features": {
                "keywords": [
                    "医药行业",
                    "推荐评级",
                    "政策免疫",
                    "二线细分龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[推荐评级]医药行业周报：布局政策免疫品种 推荐二线细分龙头",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报:《我不是药神》引热议,持续看好创新药板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "我不是药神",
                    "创新药板块"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "创新药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业周报:《我不是药神》引热议,持续看好创新药板块",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]